Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial. 7. Juni 2016 Mey, U.J.M., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T., Jehner, P., Rauh, J., Taverna, C.J., Schmid, M., Schmidt-Hieber, M., Doerfel, S., Fischer, N., Ruefer, A., Ziske, C., Knauf, W., Cathomas, R., von Moos, R., Hitz, F., Sauter, R., Hiendlmeyer, E., Cantoni, N., Bargetzi, M., Driessen, C., 2016. Br. J. Haematol. 176(5), 770–782. doi:10.1111/bjh.14481 Abstract The PAZOREAL Non-Interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changing Metastatic Renal Cell Carcinoma Treatment Landscape. Goebell, P., Doehn, C., Grüllich, C., Steiner, T., Ehneß, R., Welslau, M., 2016. Ann Oncol 27(suppl_6), 852P. doi:10.1093/annonc/mdw373 Abstract… Weiterlesen MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Schmid, P., Ferreira, M., Dubey, S., Zaiss, M., Harper-Wynne, C., Makris, A., Brown, V., Kristeleit, H., Patel, G., Perelló, A., Jones, A., Mithal, N., Ruiz,… Weiterlesen